白斑治療におけるMK-6194の臨床試験（MK-6194-007）

基本情報

NCT ID

NCT06113328

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

169

治験依頼者名

Merck Sharp & Dohme LLC

概要

Researchers are looking for a new way to treat people with non-segmental vitiligo (NSV). The goal of this study is to learn about the safety of MK-6194 and how well people tolerate it. Researchers also want to learn if people who take MK-6194 have more of a decrease in the amount of vitiligo on their face compared to people who take placebo.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)